Industry leaders prioritize quality assurance protocols as biotech sector navigates patent cliffs, financing pressures, and shifting regulatory landscapes globally.
|
The global biotech industry was able to maintain some level of stability throughout 2025 due to increasing revenue (+12%), despite the fact that macroeconomic uncertainties, such as rising inflation and tighter funding have negatively impacted many biotechnology sectors. The biotech industry received $68.5 billion in financing (an increase of 11% from 2024). Although biotech companies have continued to face numerous challenges - such as impending patent expirations, rising costs, and instability caused by political conflicts globally - there are also many examples of new and innovative methods of financing (such as synthetic royalties and other creative contractual arrangements) by biotech firms in order to survive through these uncertain times.
Mergers and acquisitions activity within the biotech industry also had an increase in activity in 2025; however, the type of deals that were made were discipline and targeted rather than a transformational merger. The M&A activity accelerated in early 2026, with a total value of $36 billion in Q1 2026, or about 36% of the total value ($99.7 billion) of M&A activity in 2025, and average deal size of $2.7 billion, which indicates that larger and higher conviction deals are becoming more common in the biotech industry. The largest amount of activity in operational excellence came out of the oncology sector at approximately $16.8 billion in transactions over $1.0 billion, with neurology being the second largest sector at $14.4 billion.
In 2025, there was a structural change in quality assurance and how venture capital invested. Late-stage VC investments increased while early-stage investment declined. Within the total US$20.6B, late-stage deals accounted for US$10B of total capital raised with 254 rounds. This concentrated activity represents a growing separation/inequity between larger and smaller companies.
As of 2026, US VCs continued this trend, with US$4.3B of VC investment in the first quarter, despite uncertainty among many businesses. Early-stage research and development (R&D) accounts for approximately 39 percent of biobucks spent by US companies on Chinese biotech. Additionally, more than 88 percent of AI-related investment was R&D focused (e.g., drug target identification, drug design, and patient recruitment for clinical trials). These two trends will continue to drive a high level of innovative activity in 2026.
Industry leaders placed regulatory adaptation at the forefront of their priorities. As they prepare for a shifting political environment in 2025, over US$370 billion of industry investment has been pledged by industry participants that will be earmarked to return manufacturing to the US with the intent of lessening the potential adverse impact of future tariffs. Balancing the increase in capital expenditures, suppliers’ cost pressures, partnerships at regional levels and new hybrid supply chain models will challenge this investment.
Business Honor views that the biotech industry's disciplined M&A strategy and operational focus represent a strategic shift toward quality-focused consolidation and sustainable growth.
.webp)
